South Korea Acute Agitation and Aggression Market Insight
Published: 30 May 2026 | Report Format: Electronic (PDF)
South Korea’s market for acute agitation and aggression therapy is experiencing high growth with a CAGR of 7.4% due to growing prevalence of psychiatric disorders, and the use of fast-acting neuropsychiatric treatments.
South Korea Acute Agitation and Aggression Market Insights Forecasts to 2035
- The South Korea Acute Agitation and Aggression Market Size Was Estimated USD 148.6 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 7.4% from 2025 to 2035
- The South Korea Acute Agitation and Aggression Market Size is Expected to rise around USD 303.4 Million by 2035
Notable Insights for the South Korea Acute Agitation and Aggression Market
- The Injectable Rapid Acting Therapies segment held around 48% market share of South Korea Acute Agitation and Aggression Market in 2025, owing to increased application in psychiatric emergency departments and acute inpatient facilities.
- The Schizophrenia-Related Agitation segment occupied almost 42% market share in 2025, attributing to high incidences of psychosis disorders and increased demand for therapies providing rapid relief from symptoms.
- The projected global revenue generated by Johnson & Johnson surpassed USD 91 billion in 2025, backed by robust neuropsychiatric treatment offerings and growing investments in treating CNS disorders.
Download the eBook (ToC)
- Increasing investments in psychiatric emergency facilities, AI-driven behavioral analysis platforms, and digital mental health tools are propelling market growth, where advanced acute agitation management therapies have been found to enhance patient stabilization efficiency by up to 39%, along with reducing intervention time in psychiatric emergencies by almost 33%.
Why Buy This Report
- Provides comprehensive analysis of neuropsychiatric therapeutics, behavioral healthcare infrastructure, and acute agitation treatment technologies influencing growth in the South Korea Acute Agitation and Aggression Market.
- Offers strategic insights into emerging technologies including intranasal CNS drug delivery systems, AI-enabled behavioral analytics platforms, digital psychiatry monitoring solutions, and rapid-response neuropharmacology frameworks.
- Supports stakeholders in evaluating competitive positioning, psychiatric healthcare investment strategies, emergency mental health treatment developments, and neurobehavioral therapeutic innovation trends across South Korea.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the South Korea Acute Agitation and Aggression Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in South Korea Acute Agitation and Aggression Market
- Johnson & Johnson
- Otsuka Pharmaceutical Co., Ltd.
- Teva Pharmaceutical Industries Ltd.
- Eli Lilly and Company
- Pfizer Inc.
- Bristol Myers Squibb
- Sumitomo Pharma Co., Ltd.
- Viatris Inc.
- Lundbeck A/S
- AbbVie Inc.
Recent Developments:
- In April 2025, Otsuka Pharmaceutical Co., Ltd. strengthened digital psychiatry integration programs supporting behavioral disorder management and AI-enabled patient monitoring technologies across hospital networks.
- In January 2025, Johnson & Johnson expanded clinical support initiatives for rapid-acting schizophrenia-associated agitation therapies focused on improving psychiatric emergency response efficiency and patient stabilization outcomes.
Market Segmentation:
South Korea Acute Agitation and Aggression Market, By Treatment Type
- Injectable Rapid-Acting Therapeutics
- Oral Antipsychotic Therapies
- Benzodiazepine-Based Treatments
- Intranasal CNS Therapeutics
South Korea Acute Agitation and Aggression Market, By Technology
- AI-Based Behavioral Monitoring Systems
- Digital Psychiatry Platforms
- Precision Neuropharmacology Technologies
- Telepsychiatry Integration Solutions
South Korea Acute Agitation and Aggression Market, By Indication
- Schizophrenia-Associated Agitation
- Bipolar Disorder Agitation
- Dementia-Related Aggression
- Substance-Induced Behavioral Disorders
Expert Views:
The South Korea acute agitation and aggression market will be experiencing steady growth due to high instances of psychiatric disorders, increased investment in mental healthcare infrastructure, and high demand for rapid-acting neuropsychiatric treatments. The adoption of AI-based behavioral tracking technologies, digital psychiatry solutions, precise CNS drugs, and telepsychiatry-supported emergency architecture will lead to an improvement in patient stabilization efficiency and create sustained demand for acute agitation and aggression drugs in South Korean psychiatric institutions and emergency departments.
Author: Komal and Radhika By Spherical Insights and Consulting